Literature DB >> 9987757

Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a.

D C Mohr1, W Likosky, A C Boudewyn, P Marietta, P Dwyer, J Van der Wende, D E Goodkin.   

Abstract

This study examines the course of patient-reported side effects during the first 4 months of treatment for multiple sclerosis (MS) with interferon beta-1a (IFN beta-1a), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills decreased over the first 2 months of treatment but did not change over the second 2 months. Loss of feeling or numbness, tingling and depression increased over 4 months, however these side effects were generally mild. Loss of feeling or numbness and tingling at 2 month follow-up were significantly related to discontinuation of IFN beta-1a by 4 month follow-up.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9987757     DOI: 10.1177/135245859800400605

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

Review 1.  [Adherence to neurologic treatment. Lessons from multiple sclerosis].

Authors:  S Kern; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

2.  Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

Authors:  Robert J Fox; Amber R Salter; Tuula Tyry; Jennifer Sun; Xiaojun You; Genevieve Laforet; Denise Campagnolo
Journal:  Int J MS Care       Date:  2013

3.  Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition.

Authors:  M R Kraus; A Schäfer; H Csef; H Faller; H Mörk; M Scheurlen
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

5.  Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines.

Authors:  Yvonne Nestoriuc; E John Orav; Matthew H Liang; Robert Horne; Arthur J Barsky
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

6.  Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis.

Authors:  L Shinto; G Marracci; S Baldauf-Wagner; A Strehlow; V Yadav; L Stuber; D Bourdette
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-01-25       Impact factor: 4.006

7.  Neuroticism, Side Effects, and Health Perceptions Among HIV-Infected Individuals on Antiretroviral Medications.

Authors:  Mallory O Johnson; Torsten B Neilands
Journal:  J Clin Psychol Med Settings       Date:  2007-03

8.  Noncompliance with Treatment of Neurologic Disease.

Authors:  Jeffrey S. Nicholl
Journal:  Curr Treat Options Neurol       Date:  2002-11       Impact factor: 3.598

9.  Improving compliance with interferon-beta therapy in patients with multiple sclerosis.

Authors:  Emilio Portaccio; Maria Pia Amato
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Authors:  Peter J Jongen; Gerald Hengstman; Raymond Hupperts; Hans Schrijver; Job Gilhuis; Joseph H Vliegen; Erwin Hoogervorst; Marc van Huizen; Eric van Munster; Johnny Samijn; Els de Schryver; Theodora Siepman; Martijn Tonk; Eveline Zandbergen; Jacques ten Holter; Ruud van der Kruijk; George Borm
Journal:  BMC Neurol       Date:  2011-03-30       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.